

## Special Issue

# Human Papillomavirus, Vaccines and Women's Health

### Message from the Guest Editor

The main objective of this Special Issue is to provide novel interesting insights regarding HPV vaccination and its potential implications for women's health of HPV vaccination to the scientific community, moving from primary and secondary prevention of cervical dysplasia and vulvar/anal condylomas to other non-gynecological issues including proctological diseases, head & neck and lung malignancies, as well as HPV-related couple fertility problems. Furthermore, we especially welcome original research papers and review articles providing high-quality rigorous novel insights regarding biological issues related to HPV vaccination (cross-protection, mechanisms of immunological escape, etc.), as well as epidemiological and community studies investigating the issues of HPV vaccination initiatives all over the world. With the hope of an enthusiastic participation of the scientific community, we launch here the *Vaccines* Special Issue entitled: "Human Papillomavirus, Vaccines and Women's Health."

### Guest Editor

Dr. Marco Petrillo

Gynecologic and Obstetric Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy

### Deadline for manuscript submissions

closed (31 March 2022)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/75515](https://mdpi.com/si/75515)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).